1,721,019 research outputs found
Gender impact on pancreatic neuroendocrine neoplasm (PanNEN) prognosis according to survival nomograms
No full textPurpose: Personalizing care and outcome evaluation are important aims in the field of NEN and nomograms may represent useful tools for clinicians. Of note, gender difference is being progressively more considered in NEN care, as it may also impact on survival. This systematic review aims to describe and analyze the available nomograms on pancreatic NENs (PanNENs) to identify if gender differences are evaluated and if they could impact on patients’ management and prognosis. Methods: We performed an electronic-based search using PubMed updated until June 2024, summarizing the available evidence of gender impact on PanNEN survival outcomes as emerges from published nomograms. Results: 34 articles were identified regarding prognostic nomograms in PanNEN fields. The most included variables were age, tumor grade, tumor stage, while only 5 papers (14.7%) included sex as one of the key model variables with a significant impact on patients’ prognosis. These 5 studies analyzed a total of 18,920 PanNENs. 3 studies found a significant impact of sex on overall survival (OS), whereas the remaining 2 studies showed no significant impact of sex on OS. Conclusions: Gender difference is being progressively more considered in PanNEN diagnosis, care and survival. Nomograms represent a potentially useful tool in patients’ management and in outcomes prediction in the field of PanNENs. A key role of sex in the prognosis of PanNENs has been found in few models, while definitive conclusions couldn’t be drawn. Future studies are needed to finally establish gender impact on PanNEN prognosis
Gender perspective in Lung Neuroendocrine Tumors: a critical review
No full textBackground: The role of gender has gained attention in oncology. In the setting of lung neuroendocrine tumors (L-NETs) the existence of differences between male and females has been suggested, but no clear-cut data are available. We aim to provide a critical analysis of the existing literature regarding sex role in L-NETs. Methods: We performed an extensive search of the available literature to provide a critical narrative review focused on key topics as epidemiology, histopathological and molecular features, functioning syndromes, prognosis and response/toxicity to treatments in L-NETs according to sex. Results: Female patients are more likely to have a L-NET than males. The reasons underlying this gender differences are still unclear; a biologic mechanism for the sex difference is possible, through a role for hormones in regulating gene expression and promoting neuroendocrine cell proliferation. A difference in immunohistochemical biomarkers has been found; thyroid transcription factor-1 (TTF-1) expression appears to be associated with female gender; at molecular level in the majority of studies L-NET mutational profile is not stratified for sex. In terms of prognosis, a correlation between male gender and a more aggressive disease has been found. Patient's gender has been recognized as a key modulator in the response/resistance to anticancer treatments, however for L-NETs the available data regarding the activity of different treatments and their toxicities are scarce as in clinical trials designed for L-NETs a stratified evaluation of drugs' activity according to patients' sex is largely missing. Conclusions: There is emerging evidence suggesting a gender role in L-NETs, however further studies are needed to better understand the pathogenesis of these tumors and to plan tailored treatments
Carcinoide timico in paziente affetta da sindrome da neoplasie endocrine multiple di tipo 1 (MEN1): ruolo dello screening radiologico e medico-nucleare
No full textNeuroendocrine Tumors and Survival Rates in Multiple Endocrine Neoplasia Type 1 Patients: Impact of Gender Difference
No full textIntroduction: Multiple endocrine neoplasia type 1 (MEN-1) is the most common inherited syndrome associated with NET development and gender-specific differences are emerging in neuroendocrine tumors (NETs). This study aimed to analyze gender difference in a single cohort of MEN-1 patients focusing on duodeno-pancreatic (DP)-NET and survival rates. Methods: MEN-1 patients referred to the Endocrinology Unit of the "Federico II"University of Naples, ENETS CoE, were retrospectively evaluated. Results: Among 100 MEN-1 patients enrolled, 59 (59%) were female and 41 (41%) male, and mean age at diagnosis was 39.4 years (range 5-86). No statistically significant association was identified between MEN-1 clinical manifestations and gender (primary hyperparathyroidism [PHPT] p: 1.0, DP-NET p: 0.83, pituitary adenoma [PA] p: 0.84, lung NET p: 0.64, and thymic NET p: 0.10), and similarly, age at diagnosis of MEN-1 and its individual manifestations was similar between genders. Survival analysis revealed no statistically significant difference between genders in DP-NET patients regarding progression disease p: 1.0 and death p: 1.0. Mean progression-free survival (PFS) of patients with DP-NET was 98.6 months (range 3-288), and mean overall survival (OS) was 130.1 months (range 3-444 months), without differences between genders (PFS p: 0.67 and OS p: 0.60). The Kaplan-Meier survival curves for PFS and OS showed no differences between genders (PFS p: 0.92; OS p: 0.87). Conclusion: In this MEN-1 cohort, no gender differences in the occurrence of PHPT, PA, DP-NET, lung NET, and thymic NET, nor in survival outcomes including PFS and OS within the DP-NET subcohort, emerged. Therefore, this study supports similar screening and follow-up for both male and female MEN-1 patients
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches
Full text linkNeuroendocrine neoplasms (NENs) are a heterogeneous group of tumors, their treatment being challenging and requiring a multidisciplinary approach. Though the only curative treatment is surgery, up to 50% of patients are diagnosed with metastatic disease. In the last years, neoadjuvant chemo(radio)therapy has become part of the standard of care in the treatment of different cancer types. However, evidence of its efficacy and safety in NEN patients has not yet been confirmed in the literature. The aim of the present review is to perform an extensive review of the scientific evidence for neoadjuvant therapy in patients with gastroenteropancreatic and thoracic NENs
- …
